Jefferson Health

Pilot Study of Anti-Oxidant Supplementation with N-Acetyl Cysteine in Stage 0/I Breast Cancer

IRB Protocol #: 12D.396


  • Anti-oxidant supplements have been shown to have some general health benefits in some women receiving treatment for breast cancer.
  • The purpose of this study is to determine whether or not there are measurable effects on breast tumors in response to a very strong anti-oxidant called N-Acetyl Cysteine (or NAC) in women with stage 0/I breast cancer.
  • This treatment is administered to women with breast cancer between their initial biopsy and definitive surgery.
  • Up to 35 patients may participate in this study at Thomas Jefferson University.


  • An intravenous infusion of NAC will be given each week, and an oral dose of NAC will be taken daily  (administered during the period between your biopsy and definite surgery).
  • Each infusion is given over approximately one hour and approximately three doses are given over the course of three weeks.
  • All treatments are provided free of charge to the participant.

Inclusion Criteria:

  • Females Age > 18
  • Women diagnosed with stage 0/I breast cancer by biopsy
  • Awaiting surgery, which will either consist of a lumpectomy or mastectomy
  • Cannot be pregnant or breastfeeding
  • Must not be on any concurrent anti-cancer chemotherapy within the last four weeks
  • Must be treated at Thomas Jefferson University Hospital

Contact Information:

Michael J. Matthews